Literature DB >> 11819306

Effect of cytokines on liver necrosis.

Yan-Yan Yu, Chong-Wen Si, Xiu-Lan Tian, Qun He, Hai-Peng Xue.   

Abstract

AIM:To investigate the effect of cytokines on the liver necrosis.
METHODS: rIL (interleukin)-1, rIL-6, rIFN (interferon), rTNF (tumor necrosis factor) -alpha with or without D-galactosamine (D-GAL) were injected into the abdominal cavity of mice separately.ALT, TBIL (total bilirubin) and histological changes were observed.
RESULTS: There was no effect on hepatocyte of normal mice after injection of rIL-1, rIL-6, rIFN alone or together. The serum total bilirubin (TBIL) and liver necrosis of mice increased after rTNF-alpha, rIL-6 or rIFN were used separately with D-GAL. The TBIL level (&mgr;mol/L)was 46.19 plus minus 10.62, 44.55 plus minus 12.9 and 41.94 plus minus 14.9, higher than that caused by D-GAL alone (TBIL, 26.67&mgr;mol/L plus minus 11.14&mgr;mol/L). The serum TBIL of mice and the degree of liver necrosis increased after injection of IL-1, IL-6 with D-GAL and rTNF-alpha.
CONCLUSION: Cytokines, like IL-1, IL-6, IFN&agr and TNF-&agr;joined in the process of hepatocyte necrosis.They can enhance the degree of liver necrosis induced by D-GAL.

Entities:  

Year:  1998        PMID: 11819306      PMCID: PMC4761547          DOI: 10.3748/wjg.v4.i4.311

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  11 in total

1.  [The effect of tumor necrosis factor alpha on hepatic necrosis in viral hepatitis].

Authors:  Y Yu; C Si; Z Lang
Journal:  Zhonghua Nei Ke Za Zhi       Date:  1996-01

2.  The acute-phase response protects mice from D-galactosamine sensitization to endotoxin and tumor necrosis factor-alpha.

Authors:  J M Alcorn; J Fierer; M Chojkier
Journal:  Hepatology       Date:  1992-01       Impact factor: 17.425

Review 3.  Cytokines and alcoholic liver disease.

Authors:  C McClain; D Hill; J Schmidt; A M Diehl
Journal:  Semin Liver Dis       Date:  1993-05       Impact factor: 6.115

4.  Elevated serum interleukin-6 levels in patients with acute hepatitis.

Authors:  Y Sun; K Tokushige; E Isono; K Yamauchi; H Obata
Journal:  J Clin Immunol       Date:  1992-05       Impact factor: 8.317

5.  Interleukin-1 and interleukin-2 activity in chronic hepatitis B virus infection.

Authors:  C Anastassakos; G J Alexander; R A Wolstencroft; J A Avery; B C Portmann; G S Panayi; D C Dumonde; A L Eddleston; R Williams
Journal:  Gastroenterology       Date:  1988-04       Impact factor: 22.682

6.  Involvement of a serine protease in tumour-necrosis-factor-mediated cytotoxicity.

Authors:  P Suffys; R Beyaert; F Van Roy; W Fiers
Journal:  Eur J Biochem       Date:  1988-12-01

7.  Serum interleukin 6 levels in patients with chronic hepatitis B.

Authors:  S Kakumu; T Shinagawa; T Ishikawa; K Yoshioka; T Wakita; Y Ito; M Takayanagi; N Ida
Journal:  Am J Gastroenterol       Date:  1991-12       Impact factor: 10.864

8.  Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients.

Authors:  A Khoruts; L Stahnke; C J McClain; G Logan; J I Allen
Journal:  Hepatology       Date:  1991-02       Impact factor: 17.425

9.  Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis.

Authors:  R González-Amaro; C García-Monzón; L García-Buey; R Moreno-Otero; J L Alonso; E Yagüe; J P Pivel; M López-Cabrera; E Fernández-Ruiz; F Sánchez-Madrid
Journal:  J Exp Med       Date:  1994-03-01       Impact factor: 14.307

10.  Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine-treated mice.

Authors:  V Lehmann; M A Freudenberg; C Galanos
Journal:  J Exp Med       Date:  1987-03-01       Impact factor: 14.307

View more
  8 in total

1.  Preliminary results of Thymosin-a1 versus interferon-alpha-treatment in patients with HBeAg negative and serum HBV DNA positive chronic hepatitis B.

Authors:  L Zhuang; J You; B Z Tang; S Y Ding; K H Yan; D Peng; Y M Zhang; L Zhang
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

2.  Plasma endothelin in patients with endotoxemia and dynamic comparison between vasoconstrictor and vasodilator in cirrhotic patients.

Authors:  F Liu; J X Li; C M Li; X S Leng
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

3.  A randomized controlled clinical trial on the treatment of Thymosin a1 versus interferon-alpha in patients with hepatitis B.

Authors:  J You; L Zhuang; B Z Tang; W B Yang; S Y Ding; W Li; R X Wu; H L Zhang; Y M Zhang; S M Yan; L Zhang
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

4.  Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study.

Authors:  Jing You; Lin Zhuang; Hong-Ying Cheng; Shou-Ming Yan; Lan Yu; Jun-Hua Huang; Bao-Zhang Tang; Meng-Ling Huang; Yong-Liang Ma; Virasakdi Chongsuvivatwong; Hutcha Sriplung; Alan Geater; Yan-Wei Qiao; Rong-Xue Wu
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

5.  Effect of cholecystokinin on cytokines during endotoxic shock in rats.

Authors:  Y L Ling; A H Meng; X Y Zhao; B E Shan; J L Zhang; X P Zhang
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

6.  TECA hybrid artificial liver support system in treatment of acute liver failure.

Authors:  Y L Xue; S F Zhao; Y Luo; X J Li; Z P Duan; X P Chen; W G Li; X Q Huang; Y L Li; X Cui; D G Zhong; Z Y Zhang; Z Q Huang
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

7.  The mRNA expression patterns of tumor necrosis factor-alpha and TNFR-I in some vital organs after thermal injury.

Authors:  Wen-Hui Fang; Yong-Ming Yao; Zhi-Guo Shi; Yan Yu; Ye Wu; Lian-Rong Lu; Zhi-Yong Sheng
Journal:  World J Gastroenterol       Date:  2003-05       Impact factor: 5.742

8.  The protective mechanism of Yisheng Injection against hepatic ischemia reperfusion injury in mice.

Authors:  Feng Cheng; You-Ping Li; Jing-Qiu Cheng; Li Feng; Sheng-Fu Li
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.